Table 1. Open in new tab Demographic...

	Total (n = 375)	NFAT (n = 215)	CPA-MACS (n = 138)	CPA-CS (n = 22)	P value (Kruskal–Wallis)	P value (group comparison)
Demographics
Age, years (IQR)	61 (52-70)	59 (51-68)	66 (57.75-74)	46 (30.75-59.25)	<.001	<.001^a .001^b <.001^c
Women, n (%)	223 (59.5)	128 (59.5)	78 (56.5)	17 (77.3)	.183
BMI, kg/m² (IQR)	29.2 (25.1-33.4)	29.6 (25.5-34.4)	28.3 (23.8-32.5)	30.2 (27.1-37.4)	.020	.039^a 1.000^b .141^c
NAPACA-related comorbidities
Hypertension, n (%) Unknown	193 (54.2) n = 19	91 (44.2) n = 9	89 (68.5) n = 8	13 (65.0) n = 2	<.001
Diabetes, n (%) Unknown	91 (25.7) n = 17	47 (22.8) n = 9	39 (29.6) n = 6	6 (30.0) n = 2	.349
Hormone results
Cortisol after 1 mg DST, nmol/L (IQR)	45 (30-84)	32 (28-39)	86 (65.5-127)	408 (285-578)	<.001	<.001^a <.001^b .009^c
ACTH, ng/L (IQR) Unknown	12.1 (6.3-20) n = 41	15.7 (10.1-23.6) n = 22	7.5 (5.0-14.1) n = 19	5.0 (5.0-5.4)	<.001	<.001^a <.001^b .010^c
DHEAS, μmol/L (IQR) Unknown	1.81 (0.8-3.2) n = 11	2.43 (1.13-4.16) n = 10	1.14 (0.59-2.36) n = 1	0.65 (0.35-0.95)	<.001	<.001^a <.001^b .049^c
Tumour characteristics
Maximum diameter, cm (IQR)^d Unknown	2.3 (1.6-3.0) n = 6	1.8 (1.4-2.5) n = 4	2.8 (2.1-3.7) n = 2	3.2 (2.75-3.85)	<.001	<.001^a <.001^b .339^c
Unilateral, n (%)	310 (82.6)	191 (88.8)	101 (73.2)	18 (81.8)	<.001
Hounsfield units (IQR) Unknown	7 (−1.5 to 16) n = 86	5 (−2 to 16.5) n = 42	8 (1.5-15) n = 39	12 (3.6-23) n = 5	.154

Total (n = 375)

NFAT (n = 215)

CPA-MACS (n = 138)

CPA-CS (n = 22)

P value (Kruskal–Wallis)

P value (group comparison)

Demographics

Age, years (IQR)

61 (52-70)

59 (51-68)

66 (57.75-74)

46 (30.75-59.25)

<.001

<.001^a
.001^b
<.001^c

Women, n (%)

223 (59.5)

128 (59.5)

78 (56.5)

17 (77.3)

.183

BMI, kg/m² (IQR)

29.2 (25.1-33.4)

29.6 (25.5-34.4)

28.3 (23.8-32.5)

30.2 (27.1-37.4)

.020

.039^a
1.000^b
.141^c

NAPACA-related comorbidities

Hypertension, n (%)
Unknown

193 (54.2)
n = 19

91 (44.2)
n = 9

89 (68.5)
n = 8

13 (65.0)
n = 2

<.001

Diabetes, n (%)
Unknown

91 (25.7)
n = 17

47 (22.8)
n = 9

39 (29.6)
n = 6

6 (30.0)
n = 2

.349

Hormone results

Cortisol after 1 mg DST, nmol/L (IQR)

45 (30-84)

32 (28-39)

86 (65.5-127)

408 (285-578)

<.001

<.001^a
<.001^b
.009^c

ACTH, ng/L (IQR)
Unknown

12.1 (6.3-20)
n = 41

15.7 (10.1-23.6)
n = 22

7.5 (5.0-14.1)
n = 19

5.0 (5.0-5.4)

<.001

<.001^a
<.001^b
.010^c

DHEAS, μmol/L (IQR)
Unknown

1.81 (0.8-3.2)
n = 11

2.43 (1.13-4.16)
n = 10

1.14 (0.59-2.36)
n = 1

0.65 (0.35-0.95)

<.001

<.001^a
<.001^b
.049^c

Tumour characteristics

Maximum diameter, cm (IQR)^d
Unknown

2.3 (1.6-3.0)
n = 6

1.8 (1.4-2.5)
n = 4

2.8 (2.1-3.7)
n = 2

3.2 (2.75-3.85)

<.001

<.001^a
<.001^b
.339^c

Unilateral, n (%)

310 (82.6)

191 (88.8)

101 (73.2)

18 (81.8)

<.001

Hounsfield units (IQR)
Unknown

7 (−1.5 to 16)
n = 86

5 (−2 to 16.5)
n = 42

8 (1.5-15)
n = 39

12 (3.6-23)
n = 5

.154

	Total (n = 375)	NFAT (n = 215)	CPA-MACS (n = 138)	CPA-CS (n = 22)	P value (Kruskal–Wallis)	P value (group comparison)
Demographics
Age, years (IQR)	61 (52-70)	59 (51-68)	66 (57.75-74)	46 (30.75-59.25)	<.001	<.001^a .001^b <.001^c
Women, n (%)	223 (59.5)	128 (59.5)	78 (56.5)	17 (77.3)	.183
BMI, kg/m² (IQR)	29.2 (25.1-33.4)	29.6 (25.5-34.4)	28.3 (23.8-32.5)	30.2 (27.1-37.4)	.020	.039^a 1.000^b .141^c
NAPACA-related comorbidities
Hypertension, n (%) Unknown	193 (54.2) n = 19	91 (44.2) n = 9	89 (68.5) n = 8	13 (65.0) n = 2	<.001
Diabetes, n (%) Unknown	91 (25.7) n = 17	47 (22.8) n = 9	39 (29.6) n = 6	6 (30.0) n = 2	.349
Hormone results
Cortisol after 1 mg DST, nmol/L (IQR)	45 (30-84)	32 (28-39)	86 (65.5-127)	408 (285-578)	<.001	<.001^a <.001^b .009^c
ACTH, ng/L (IQR) Unknown	12.1 (6.3-20) n = 41	15.7 (10.1-23.6) n = 22	7.5 (5.0-14.1) n = 19	5.0 (5.0-5.4)	<.001	<.001^a <.001^b .010^c
DHEAS, μmol/L (IQR) Unknown	1.81 (0.8-3.2) n = 11	2.43 (1.13-4.16) n = 10	1.14 (0.59-2.36) n = 1	0.65 (0.35-0.95)	<.001	<.001^a <.001^b .049^c
Tumour characteristics
Maximum diameter, cm (IQR)^d Unknown	2.3 (1.6-3.0) n = 6	1.8 (1.4-2.5) n = 4	2.8 (2.1-3.7) n = 2	3.2 (2.75-3.85)	<.001	<.001^a <.001^b .339^c
Unilateral, n (%)	310 (82.6)	191 (88.8)	101 (73.2)	18 (81.8)	<.001
Hounsfield units (IQR) Unknown	7 (−1.5 to 16) n = 86	5 (−2 to 16.5) n = 42	8 (1.5-15) n = 39	12 (3.6-23) n = 5	.154

Table 1.

Open in new tab

Demographic parameters, hormonal, and radiological data of patients with non–aldosterone-producing adrenocortical adenomas.

	Total (n = 375)	NFAT (n = 215)	CPA-MACS (n = 138)	CPA-CS (n = 22)	P value (Kruskal–Wallis)	P value (group comparison)
Demographics
Age, years (IQR)	61 (52-70)	59 (51-68)	66 (57.75-74)	46 (30.75-59.25)	<.001	<.001^a .001^b <.001^c
Women, n (%)	223 (59.5)	128 (59.5)	78 (56.5)	17 (77.3)	.183
BMI, kg/m² (IQR)	29.2 (25.1-33.4)	29.6 (25.5-34.4)	28.3 (23.8-32.5)	30.2 (27.1-37.4)	.020	.039^a 1.000^b .141^c
NAPACA-related comorbidities
Hypertension, n (%) Unknown	193 (54.2) n = 19	91 (44.2) n = 9	89 (68.5) n = 8	13 (65.0) n = 2	<.001
Diabetes, n (%) Unknown	91 (25.7) n = 17	47 (22.8) n = 9	39 (29.6) n = 6	6 (30.0) n = 2	.349
Hormone results
Cortisol after 1 mg DST, nmol/L (IQR)	45 (30-84)	32 (28-39)	86 (65.5-127)	408 (285-578)	<.001	<.001^a <.001^b .009^c
ACTH, ng/L (IQR) Unknown	12.1 (6.3-20) n = 41	15.7 (10.1-23.6) n = 22	7.5 (5.0-14.1) n = 19	5.0 (5.0-5.4)	<.001	<.001^a <.001^b .010^c
DHEAS, μmol/L (IQR) Unknown	1.81 (0.8-3.2) n = 11	2.43 (1.13-4.16) n = 10	1.14 (0.59-2.36) n = 1	0.65 (0.35-0.95)	<.001	<.001^a <.001^b .049^c
Tumour characteristics
Maximum diameter, cm (IQR)^d Unknown	2.3 (1.6-3.0) n = 6	1.8 (1.4-2.5) n = 4	2.8 (2.1-3.7) n = 2	3.2 (2.75-3.85)	<.001	<.001^a <.001^b .339^c
Unilateral, n (%)	310 (82.6)	191 (88.8)	101 (73.2)	18 (81.8)	<.001
Hounsfield units (IQR) Unknown	7 (−1.5 to 16) n = 86	5 (−2 to 16.5) n = 42	8 (1.5-15) n = 39	12 (3.6-23) n = 5	.154

	Total (n = 375)	NFAT (n = 215)	CPA-MACS (n = 138)	CPA-CS (n = 22)	P value (Kruskal–Wallis)	P value (group comparison)
Demographics
Age, years (IQR)	61 (52-70)	59 (51-68)	66 (57.75-74)	46 (30.75-59.25)	<.001	<.001^a .001^b <.001^c
Women, n (%)	223 (59.5)	128 (59.5)	78 (56.5)	17 (77.3)	.183
BMI, kg/m² (IQR)	29.2 (25.1-33.4)	29.6 (25.5-34.4)	28.3 (23.8-32.5)	30.2 (27.1-37.4)	.020	.039^a 1.000^b .141^c
NAPACA-related comorbidities
Hypertension, n (%) Unknown	193 (54.2) n = 19	91 (44.2) n = 9	89 (68.5) n = 8	13 (65.0) n = 2	<.001
Diabetes, n (%) Unknown	91 (25.7) n = 17	47 (22.8) n = 9	39 (29.6) n = 6	6 (30.0) n = 2	.349
Hormone results
Cortisol after 1 mg DST, nmol/L (IQR)	45 (30-84)	32 (28-39)	86 (65.5-127)	408 (285-578)	<.001	<.001^a <.001^b .009^c
ACTH, ng/L (IQR) Unknown	12.1 (6.3-20) n = 41	15.7 (10.1-23.6) n = 22	7.5 (5.0-14.1) n = 19	5.0 (5.0-5.4)	<.001	<.001^a <.001^b .010^c
DHEAS, μmol/L (IQR) Unknown	1.81 (0.8-3.2) n = 11	2.43 (1.13-4.16) n = 10	1.14 (0.59-2.36) n = 1	0.65 (0.35-0.95)	<.001	<.001^a <.001^b .049^c
Tumour characteristics
Maximum diameter, cm (IQR)^d Unknown	2.3 (1.6-3.0) n = 6	1.8 (1.4-2.5) n = 4	2.8 (2.1-3.7) n = 2	3.2 (2.75-3.85)	<.001	<.001^a <.001^b .339^c
Unilateral, n (%)	310 (82.6)	191 (88.8)	101 (73.2)	18 (81.8)	<.001
Hounsfield units (IQR) Unknown	7 (−1.5 to 16) n = 86	5 (−2 to 16.5) n = 42	8 (1.5-15) n = 39	12 (3.6-23) n = 5	.154

Categorical variables are reported as n (%); statistical comparison was performed by χ² test. Continuous variables are reported as median (IQR), and statistical analyses were performed by the Kruskal–Wallis test followed by Dunn's post hoc test.

Abbreviations: 1 mg DST, 1 mg overnight dexamethasone suppression test; ACTH, adrenocorticotropin hormone; BMI, body mass index; CPA-CS, cortisol-producing adenoma with overt Cushing's syndrome; CPA-MACS, cortisol-producing adenoma with mild autonomous cortisol secretion; DHEAS, dehydroepiandrosterone sulphate; NFAT, non-functioning adrenal tumour.

^aNFAT vs CPA-MACS.

^bNFAT vs CPA-CS.

^cMACS vs CPA-CS.

^dFor bilateral tumours, the maximum diameter of the larger adrenal mass was considered.

This Feature Is Available To Subscribers Only